In ImmunoCellular’s follow-on Phase II trial of ICT-107, there are 213 patients enrolled to date, of which 100 patients have been either randomized (or treated with the product) or are waiting to complete radiation therapy prior to treatment. The Company recently announced that its Phase II trial is now on-going at 25 sites, with patients enrolled in leading medical centers such as Mass General Cancer Center and the Dana Farber Cancer Institute. ImmunoCellular plans to continue enrollment for a short time to ensure enough patients will be available for the data analysis. The trial, as originally designed, was to enroll over 200 patients to treat at least 102 patients with HLA-A1/A2 immunological subtypes.“The continued impressive survival data we have seen to date and the timely enrollment in our ongoing Phase II trial, further build our confidence that targeting CSCs may provide a breakthrough in the treatment of GBM,” said Manish Singh, Ph.D., President and CEO of ImmunoCellular. “As we complete enrollment of our Phase II trial, we look forward to obtaining patient data.” About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com. Forward-Looking Statements for ImmunoCellular Therapeutics This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials in statistically significant larger patient populations; and the risks associated with adhering to clinical timeframes. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.